ClinicalTrials.gg
CompletedNCT04641338DIPICORUpdated May 11, 2026

Fixed Combination of Dipyrone and Codeine for Controlling Pain After Pelvic-abdominal Surgery

A Phase 3 interventional study of Fixed dose combination Dipyrone and Codeine and Dipyrone in Pain, Postoperative, sponsored by Brazilian Clinical Research Institute. Completed at 3 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Brazilian Clinical Research Institute · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
491
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Pain, Postoperative with a site in Brazil — 8 open to participants now, 8 under way, 1 of them phase 3. Pain, Postoperative · Brazil.

Enrollment
Largest of 53
491 · median 70
Started
2023
with 3 others
Phase 3
5 of 56
none open now
Registered
44th of 56
by date

Among the 56 studies in Pain, Postoperative with a site in Brazil, this one has the largest enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 3, and was the 44th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 56 studies in Pain, Postoperative with a site in Brazil are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Pain, Postoperative with a site in Brazil, or all of them as a file.
02

Study summary

Phase III clinical trial, multicentre, superiority, randomized, open, parallel groups, with active control and use of postoperative oral medication (multiple doses of medication).

Read the detailed description

The main objective is to evaluate the effectiveness and safety of the association in relation to the isolated use of medicines.

03

Conditions studied

  • Pain, Postoperative

Keywords

  • Codeine
  • pain
  • Dipyrone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 years or older;
  • Be able to sign the ICF approved by the IEC and to perform and understand all the study procedures and instructions;
  • Show post-anesthesia recovery with a score greater than or equal to 8 on the modified Aldrete and Kroulik Scale;
  • Experience pain intensity according to the visual analogue scale (VAS) of 3.0 to 10 cm (moderate to severe pain) immediately after surgery;
  • Have an elective open abdominal-pelvic surgery scheduled, not due to malignant neoplasm, to be performed within 4 weeks of screening;
  • Estimated hospital stay for at least 48 hours after the procedure.

Exclusion criteria

Exclusion Criteria:

  • Surgical complications during participant enrollment in the research;
  • Surgery with indication for treatment of confirmed or suspected malignant neoplasm;
  • Chronic use of any non-steroidal anti-inflammatory drugs;
  • Suspected paralytic ileus or intestinal obstruction;
  • Inability to use oral drugs postoperatively;
  • Videolaparoscopic surgery;
  • History of chronic and current use of opioids or other analgesics;
  • Use of concomitant modalities of intravenous or neuraxial analgesia (spinal and epidural) with placement of an epidural catheter for use in the postoperative period, or regional blockade, where the expected duration of analgesia administered intravenously or neuroaxially is maintained after 24 hours of the surgical procedure or randomization, whichever occurs first;
  • Use of therapy in the last 24 hours prior to surgery;
  • Participants with uncontrollable vomiting present in the postoperative period;
  • Abusive user of alcohol or illicit drugs;
  • Use of drugs with potential interaction with the study drugs;
  • Allergy, , or known to the use of ingredients of the study drug;
  • Psychiatric or social disorders that prevent the appropriate compliance with the protocol;
  • Demonstrate inability to understand and perform current pain assessments in the study;
  • Women who are pregnant, breastfeeding, planning to become pregnant, or who have a positive urine pregnancy test.
  • Participants who test positive for COVID-19 (upon presentation of the test report at the time of screening or prior to randomization);
  • Participation in another clinical trial within less than one year (unless the participation is warranted by the principal investigator);
  • Presence of decompensated diabetes mellitus;
  • History of decompensated obstructive or restrictive respiratory disease;
  • Current symptoms or past history of gastrointestinal bleeding;
  • History of blood dyscrasia or chronic disease of any nature that contraindicates the participant's participation at the investigator's discretion;
  • Inability to understand and perform the pain assessments during the study;
  • Hypersensitivity or contraindication to the use of ingredients of the study drugs;
  • Grade III obesity ( above 40);
  • Presence of one or more flu-like symptoms, such as: fever, cough, dyspnea, myalgia and fatigue, respiratory symptoms, gastrointestinal symptoms (such as diarrhea) within 14 days prior to the screening or randomization visit;
  • Other serious comorbidities at the investigators' discretion (such as history of renal, hepatic, cardiac or other peptic ulcer);
  • Any clinical condition that the investigator considers to pose a risk to the patient or interfere with study conduction.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
491 participants (actual)

Study arms

  • Experimental
    Combination therapy group

    Drug: Fixed dose combination Dipyrone and Codeine

  • Active comparator
    Dipyrone

    Drug: Dipyrone

  • Active comparator
    Codeine

    Drug: Codeine

Interventions

  • DrugFixed dose combination Dipyrone and Codeine

    Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours

  • use of 1000 mg dipyrone every 6 hours

  • 30 mg codeine every 6 hours.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving at least 50% of maximum pain relief within 6 hours

    Proportion of participants achieving at least 50% of maximum pain relief within 6 hours after first drug administration, through the assessment of total pain relief (TOTPAR) after first drug administration. TOTPAR is calculated from the result of the 5-point categorical pain relief scale (adapted PAR scale, with the 5 categories: 1-no relief, 2-mild relief, 3-moderate relief, 4-a lot of relief, and 5-complete relief). The PAR will be evaluated 30 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours after drug administration, so that the TOTPAR can take into account the progress of pain relief at 8 different timepoints.

    Time frame: 6 hours

Secondary outcomes

  1. Pain assessment by the visual analogic scale score

    The average visual analogic scale score (visual analogic scale from 0 to 10 cm, where 0 = no pain and 10 = the worst imaginable pain) measured at rest and during handling in subsequent medication.

    Time frame: 6 hours

  2. Proportion of participants who achieve at least 50% pain reduction

    Assessment of the proportion of participants who achieve at least 50% pain reduction within 6 hours, through assessment of SPID (sum of the pain intensity difference) after the first dose of study drugs;

    Time frame: 6 hours

  3. Assessment of complete pain relief

    Assessment of complete pain relief by verbal scale assessment of pain relief (VRS where 0 = no pain relief, 1 = mild pain relief, 2 = moderate pain relief, 3 = good pain relief, and 4 = excellent pain relief).

    Time frame: 72 hours

  4. Time to pain relief

    Median time to pain relief

    Time frame: During hospitalization

  5. Assessment of satisfaction with treatment by the participant

    Assessment of satisfaction with treatment by the participant using a standard categorical rating scale: Patient-reported global evaluation of Eficacy (PGE) scale of 5-points where 0=poor, 1=fair, 2=good , 3=very good, and 5=excellent response to therapy).

    Time frame: 14 days

  6. Presence of adverse events

    Time frame: 14 days

07

Study locations

3 sites
  • Associação Hospital de Caridade Ijuí - Núcleo de Ensino e Pesquisa
    Ijuí, Rio Grande do Sul, Brazil
  • Hospital Universitário São Francisco na Providência de Deus
    Bragança Paulista, São Paulo, Brazil
  • Santa Casa de Misericórdia de Votuporanga
    Votuporanga, São Paulo, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided — The data may be shared with other parties upon reasonable request to the corresponding author of the publications and after agreement with the sponsor.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2024, 11 months.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 11 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2020
First posted
Nov 23, 2020
StartActual
Mar 16, 2023
Primary completionActual
Mar 15, 2024
CompletionActual
May 17, 2024
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04641338
Lead sponsor
Brazilian Clinical Research Institute
Responsible party
Sponsor
First posted
Nov 23, 2020
Start date
Mar 16, 2023
Primary completion
Mar 15, 2024
Completion
May 17, 2024
Last update
May 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion